News Summary: Charges help cut Merck Q4 profit

Published



PROFIT DROP: Lower sales due to generic competition and one-time charges cut Merck & Co.’s fourth-quarter profit by 7 percent, to $1.4 billion, or 46 cents per share. Sales were down 5 percent, at $11.74 billion.

UNEXPECTED DELAY: Merck said it’s reviewing safety and efficacy data from a crucial late-stage patient test of its experimental osteoporosis drug. It will hold off from applying for approval of the drug, odanacatib, until 2014. It had originally planned file in the first half of this year.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.